{"id":390556,"date":"2018-11-12T00:00:00","date_gmt":"2018-11-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2018-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-21T11:26:20","modified_gmt":"2026-04-21T11:26:20","slug":"dlsfcg0005-2018-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2018-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Parkinson&#8217;s Disease | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>The Parkinson\u2019s disease (<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 with more on the horizon (e.g.,\u00a0ND-0612,\u00a0AP-CD\/LD, IPX-203), two new rescue therapies for \u201coff\u201d periods will be available in 2019 (i.e., Inbrija,\u00a0APL-130277), and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Gocovri, Nuplazid) or are in late-phase development (e.g., P2B-001, HP-3000). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase sales in the\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>\u00a0market. However, given the cost-sensitivity of\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>\u00a0patients and widespread availability of generic and\u2014for many patients\u2014therapeutically adequate agents, new\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>\u00a0brands will enter a market of intensifying competition and access challenges.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What will be the impact of forthcoming levodopa reformulations? Will they alter the\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>treatment paradigm, or be sidelined by access hurdles and\/or physician resistance?<\/li>\n<li>What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>?<\/li>\n<li>How will neurologists differentiate among current and next-generation levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which of these therapies will enjoy the greatest clinical and commercial success in this highly generic market?<\/li>\n<\/ul>\n<p><strong>Markets covered:\u00a0<\/strong>United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>28 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other\u00a0<abbr data-original-title=\"Decision Resources Group\" title=\"\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Total, diagnosed, and drug-treated prevalent cases of\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>\u00a0by country.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase II: 27\u00a0drugs; Phase III: 5 drugs; preregistration: 2 drugs. Coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Market forecast features:\u00a0<\/strong>Ten-year, annualized, drug-level sales and patient share of key\u00a0<abbr data-original-title=\"Parkinson's disease\" title=\"\">PD<\/abbr>\u00a0therapies through 2027, segmented by brands\/generics.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics,\u00a0Adamas Pharmaceuticals, Amneal Pharmaceuticals, Eisai, Hisamitsu\u00a0Pharmaceutical,\u00a0Kyowa\u00a0Hakko Kirin, Meiji Seika\u00a0Pharma, Mitsubishi Tanabe Pharma, Newron\u00a0Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals,\u00a0Pharma\u00a0Two B, Sumitomo Dainippon Pharma, Sunovion,\u00a0Takeda, Teva, UCB, US WorldMeds, Zambon Pharma.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>levodopa, amantadine, apomorphine,\u00a0AP-CD\/LD,\u00a0APL-130277, Duodopa\/Duopa, entacapone, Gocovri,\u00a0HP-3000, IPX-203,\u00a0ND-0612, Neupro, Nouriast, Nuplazid, Ongentys, Osmolex\u00a0ER,\u00a0pramipexole,\u00a0P2B-001, rasagiline, ropinirole, Rytary\/Numient, selegiline, Trerief,\u00a0Xadago.<\/p>\n","protected":false},"template":"","class_list":["post-390556","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390556\/revisions"}],"predecessor-version":[{"id":393680,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390556\/revisions\/393680"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}